Report for: Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)

Title	Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)
Published in	Trials, February 2022
DOI	10.1186/s13063-022-06049-7
Pubmed ID	35123553
Authors	Tomohisa Yamamoto, Tsutomu Fujii, Satoshi Hirano, Fuyuhiko Motoi, Goro Honda, Kenichiro Uemura, Joji Kitayama, Michiaki Unno, Yasuhiro Kodera, Hiroki Yamaue, Toshio Shimokawa, Daisuke Hashimoto, So Yamaki, Hideyuki Yoshitomi, Fumihiko Miura, Hideki Ueno, Mitsugu Sekimoto, Sohei Satoi

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
United States	1	33%
Unknown	2	67%

Type	Count	As %
Members of the public	2	67%
Practitioners (doctors, other healthcare professionals)	1	33%

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	22	100%

Readers by professional status	Count	As %
Researcher	4	18%
Lecturer	2	9%
Student > Ph. D. Student	2	9%
Student > Bachelor	2	9%
Student > Master	1	5%
Other	1	5%
Unknown	10	45%

Readers by discipline	Count	As %
Medicine and Dentistry	6	27%
Neuroscience	2	9%
Immunology and Microbiology	1	5%
Pharmacology, Toxicology and Pharmaceutical Science	1	5%
Biochemistry, Genetics and Molecular Biology	1	5%
Other	1	5%
Unknown	10	45%

Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)